Genmab
Nasdaq GMAB · 1253 Copenhagen K, Denmark
Works in Cardiovascular · Dermatology · ENT · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Oncology · Renal & urogenital · Respiratory · Women's health
Genmab is a clinical trial sponsor based in 1253 Copenhagen K, Denmark, listed as Nasdaq GMAB. It has 32 active clinical trials with 12,508 planned participants, across 12 therapeutic areas. Since 2021 it has completed 9 trials and stopped 22 early.
Trial track record · since 2021
Financials · Nasdaq GMAB
Pipeline · 32 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Genmab
Genmab is lead sponsor of 32 active clinical trials on ClinicalTrials.gov, with 12,508 planned participants, in Cardiovascular, Dermatology, ENT, GI & liver and other areas. Since 2021 it has completed 9 trials and stopped 22 early.
Genmab is based in 1253 Copenhagen K, Denmark and is listed as Nasdaq GMAB. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Genmab; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
Approve Suite is not affiliated with Genmab. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.